Navigation Links
Isis Pharmaceuticals to Present at the 14th Annual Bank of America Merrill Lynch Health Care Conference
Date:5/3/2011

CARLSBAD, Calif., May 3, 2011 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at Bank of America  Merrill Lynch's 14th Annual Health Care Conference on Tuesday, May 10, 2011 at 1:40 p.m. PT at the Encore at the Wynn in Las Vegas.

A live audio webcast of the presentation will be available on the "Investors & Media" section of the Company's Web site, www.isispharm.com.  A replay of the presentation will be available on the Isis Web site within 48 hours and will be archived for a limited time.

ABOUT ISIS PHARMACEUTICALS, INC.

Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners.  The Company has successfully commercialized the world's first antisense drug and has 24 drugs in development.  Isis' drug development programs are focused on treating cardiovascular, metabolic, and severe neurodegenerative diseases and cancer.  Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases.  Isis and Alnylam Pharmaceuticals are joint owners of Regulus Therapeutics Inc., a company focused on the discovery, development and commercialization of microRNA therapeutics.  Isis also has made significant innovations beyond human therapeutics resulting in products that other companies, including Abbott, are commercializing.  As an innovator in RNA-based drug discovery and development, Isis has designed and executed a patent strategy that has provided the Company with strong and extensive protection for Isis' drugs and technology.  Additional information about Isis is available at www.isispharm.com.


'/>"/>
SOURCE Isis Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Optimer Pharmaceuticals Expands Senior Management Team
2. Avanir Pharmaceuticals to Present at the Bank of America Merrill Lynch Healthcare Conference
3. Lexicon Pharmaceuticals Reports on Clinical Program Status and 2011 First Quarter Results
4. Amira Pharmaceuticals Announces Completion of Phase 1 Clinical Study for AM152, A Novel LPA1 Receptor Antagonist
5. Valeant Pharmaceuticals Congratulates Teva and Cephalon on Their Transaction
6. Watson Pharmaceuticals to Webcast Annual Meeting of Stockholders on May 13th
7. Valeant Pharmaceuticals to Announce 2011 First Quarter Results on May 9, 2011
8. Optimer Pharmaceuticals to Present at May 2011 Investor Conferences
9. Savient Pharmaceuticals Names Seasoned Pharma Exec Richard Crowley EVP Biopharmaceutical Operations
10. Inovio Pharmaceuticals to Present at Investor Conferences
11. Endo Pharmaceuticals Reports Strong First Quarter 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... Research and Markets has announced the addition of the "Active ... (Synthetic, Biotech), Product (mAb, Hormone) Drug (OTC, Rx), Therapy (Diabetes, Oncology, ... offering. ... global active pharmaceutical ingredients market is expected to reach USD 213.97 ... a CAGR of 6.3% from 2016 to 2021. ...
(Date:1/17/2017)... 17, 2017 Immune Pharmaceuticals (NASDAQ: ... today that it will hold a Satellite Symposium on February ... (ISAL) XVI in Munich, Germany . ... Efficacy of Immunotherapy for the maintenance of remission in ... 20 th , 2017 from 12:45 – 13:45 CET ...
(Date:1/17/2017)... Interpace Diagnostics Group, Inc., (NASDAQ: IDXG ... tests and pathology services for evaluating risks of cancer, ... January 13, 2017 from the NASDAQ Listing Qualifications notifying ... requirement of the NASDAQ Stock Market to maintain a ... The letter noted that for the last 10 ...
Breaking Medicine Technology:
(Date:1/17/2017)... CA (PRWEB) , ... January 17, 2017 , ... ... County, as well as Palm Desert, is opening a new office in San ... deep transcranial magnetic stimulation (dTMS) in Southern California, successfully treating individuals struggling with ...
(Date:1/17/2017)... ... January 17, 2017 , ... Surgeons from New York’s ... care practitioners on the latest breakthroughs in the prevention, diagnosis and treatment of ... according to eye surgeon, Jeffrey Martin, MD, FACS, Chief Executive Officer of SightMD ...
(Date:1/17/2017)... ... 17, 2017 , ... Wettstein Agencies, a Denver area firm ... throughout central Colorado, is joining local nonprofit Aurora Warms The Night to provide ... organization is committed to breaking the cycle of homelessness and poverty affecting a ...
(Date:1/17/2017)... ... January 17, 2017 , ... Physicians Education Review®, LCC (PER®) ... speaker for the 34th Annual Miami Breast Cancer Conference®, on March 9-12, 2017 ... Phil Talamo, said, “We are delighted to have Sandra Lee join us as ...
(Date:1/17/2017)... ... January 17, 2017 , ... Today, FloSports , a global leader in ... agreement as part of a long-term extension of their media partnership. The partnership, which ... some of the sport’s premier events exclusively on FloWrestling.com as well as usage of ...
Breaking Medicine News(10 mins):